Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?

References

• Chappel SC, Howless C. Re-evaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206–1212.
   PubMed Web of Science ®Google Scholar
• Shoham Z, Jacobs HS, Insler V. Luteinizing hormon its role, mechanism of action and detrimental effects when hypersecreted during the follicular phase. Fertil Steril 1993;59:1153–1161.
   PubMed Web of Science ®Google Scholar
• Andersen CY, Ziebe S, Guoliang X, Byskov AG. Requirements for human chorionic gonadotropin and recombinant human luteinizing hormone for follicular development and maturation. J Assist Reprod Genet 1999;16:425–430.
   PubMedGoogle Scholar
• Steinkampf MP, Mendelson CR, Simpson ER. Regulation by follicle-stimulating hormone of the synthesis of aromatase cytochrome P-450 in human granulosa cells. Mol Endocrinol 1987;1:465–471.
   PubMedGoogle Scholar
• Zeleznik AJ, Fairchild-Benyo D. Control of follicular development, corpus luteum funcion, and the recognition of pregnancy in higher primates. The physiology of reproduction. Vol. 2. 2nd ed.New YorkRaven Press1994pp 751–782.
   Google Scholar
• Navot D, Bergh P, Leufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies prevention and treatment. Fertil Steril 1992;58:249–261.
   PubMed Web of Science ®Google Scholar
• Beerendonk CC, van Dop PA, Braat DD, Merkus JM. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet Gynecol Surv 1998;53:439–449.
   PubMedGoogle Scholar
• Machac S, Lubusky M, Prochazka M, Streda R. Prevalence of inherited trombophilia in aptients with severe ovarian hyperstimulation syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006;150:289–292.
   PubMedGoogle Scholar
• Rizk B, Aboulghar M, Smitz J, Ron-EI R. The role of vascular endothelial growth factor and interleukins in the pathogenesys of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997;3:255–262.
   PubMed Web of Science ®Google Scholar
• Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome – views and ideas. Hum Reprod 1997;12:1129–1137.
   PubMed Web of Science ®Google Scholar
• Benadiva CA, Davis OO, Kligman I, Moomjy M, Liu HC, Rosenwaks Z. Witholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 1997;67:724–727.
   PubMed Web of Science ®Google Scholar
• Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, Parmegiani L, Pelusi G, DeAlosyo D. The use of LH activity to drive folliculogenesis: exploring uncharter territories in ovulation induction. Hum Reprod Update 2002;8:543–557.
   PubMed Web of Science ®Google Scholar
• Van Santbrink EJ, Fauser BC. Urinary follicle-stimulating hormone for normogonadotropic Clomiphene-resistant anovulatory infertility: prospective randomized comparison between low dose step-up and step-down dose regimens. J Clin Endocrinol Metab 1997;82:3597–3602.
   PubMed Web of Science ®Google Scholar
• Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Spettoli D, Taraborrelli S, Ciampaglia W. Modulation of folliculogenesis and steroidogenesis in women by graded menotropin administration. Hum Reprod 2002;17:2009–2015.
   PubMed Web of Science ®Google Scholar
• The European Recombinant LH Study Group 2001. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double blind study. J Clin Endocrinol Metab 2001;86:2607–2618.
   PubMedGoogle Scholar
• Blankstein J, Shalev J, Sadon T, Kukia EE, Rabinovici J, Pariente C, Lunenfeld B, Serr DM, Mashiach S. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 1987;47:597–602.
   PubMed Web of Science ®Google Scholar
• Navot D, Relou A, Birkenfeld A, Rabinowits R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988;159:210–215.
   PubMed Web of Science ®Google Scholar
• Chandrasekher YA, Hutchison JS, Zelinski-Wooten MB, Hess DL, Wolf DP, Stouffer RL. Initiation of periovulatory events in primate follicles using recombinant and native human luteinizing hormone to mimic the midcycle gonadotropin surge. J Clin Endocrinol Metab 1994;79:298–306.
   PubMed Web of Science ®Google Scholar
• Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 1999;84:228–232.
   PubMed Web of Science ®Google Scholar
• Karsch FJ, Weick RF, Hotchkiss J, Dierschke DJ, Knobil E. An analysis of the negative feedback control of gonadotropin secretion utilizing chronic implantation of ovarian steroids in ovariectomized rhesus monkeys. Endocrinology 1973;93:478–448.
   PubMed Web of Science ®Google Scholar
• Bassett SG, Zeleznik AJ. Acute suppression of FSH secretion by oestradiol in the ovariectomized rhesus monkey. J Reprod Fertil 1990;88:441–446.
   PubMedGoogle Scholar
• Balasch J, Fabregues F. Pregnancy after administration of high dose recombinant human LH alone to support final stages of follicular maturation in a woman with long-standing hypogonadotrophic hypogonadism. Reprod Biomed Online 2003;6:427–431.
   PubMedGoogle Scholar
• Brown JB. Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust NZ J Obstet Gynecol 1978;18:47–55.
   Google Scholar
• Fevold HL. Synergism of follicle stimulating and luteinizing hormones in producing estrogen secretion. Endocrinology 1941;28:33–36.
   Google Scholar
• Hugues JN, Soussis J, Calderon I, Balasch J, Anderson RA, Romeuon A; behalf of the Recombinant LH Study Group. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod 2005;20:629–635.
   PubMed Web of Science ®Google Scholar
• Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani1 PG. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005;20:2421–2425.
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hypersstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559–577.
   PubMed Web of Science ®Google Scholar
• Mordel N, Schenker JG. Gonadotrophin-releasing hormone agonists and ovarian hyperstimulation syndrome in assisted reproduction. Hum Reprod 1993;8:2009–2014.
   PubMedGoogle Scholar
• Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G P, Picconeri M G, Campbell A, Rowe P. Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reprod Biomed Online 2001;3:188–192; webpaper 2001/226 on web 15 October 2001.
   Google Scholar
• Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe GP, Picconeri MG, Campbell A. Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online 2002;5:104–108.
   PubMedGoogle Scholar
• Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 2005;83:309–315.
   PubMed Web of Science ®Google Scholar